Last of the Big-Time Spenders?

See allHide authors and affiliations

Science  17 Jan 2003:
Vol. 299, Issue 5605, pp. 330-333
DOI: 10.1126/science.299.5605.330

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

This article has a correction. Please see:


Much-debated university research deals backed by Amgen and Novartis appear on balance to have benefited the universities involved. But as the two deals quietly dissolve, some observers predict that their kind will not be seen again. The companies themselves, facing an anemic economy, are moving to old-fashioned contracts with individual scientists or making research deals with small companies.

View Full Text

Stay Connected to Science